Coral Laboratories Limited

CORALAB6

INE683E01017

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:51 2024-05-15 am EDT			5-day change	1st Jan Change
378.8 ^INR	+1.03%		+0.76%	-12.94%

Apr. 24	Coral Laboratories Limited Appoints Ruchi Pipara as Company Secretary, Compliance Officer and Key Managerial Personnel	CI
Mar. 29	Coral Laboratories Limited Announces Change in Registered Office Address	CI

Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022

May 27, 2022 at 07:47 am EDT

Coral Laboratories Limited reported earnings results for the fourth quarter ended March 31, 2022. For the fourth quarter, the company reported sales was INR 200.77 million compared to INR 278.16 million a year ago. Revenue was INR 216.06 million compared to INR 298.61 million a year ago. Net income was INR 25.46 million compared to INR 17.43 million a year ago. Basic earnings per share from continuing operations was INR 7.13 compared to INR 4.88 a year ago.

Latest news about Coral Laboratories Limited

Coral Laboratories Limited Appoints Ruchi Pipara as Company Secretary, Compliance Officer and Key Managerial Personnel	Apr. 24	CI
Coral Laboratories Limited Announces Change in Registered Office Address	Mar. 29	CI
Coral Laboratories Limited Announces Resignation of Shifa Memon as Company Secretary, Compliance Officer and Key Managerial Personnel	Mar. 15	CI
Coral Laboratories Limited Appoints Shifa Memon as Company Secretary and Compliance Officer, with Effect from March 9, 2024	Mar. 08	CI
Coral Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Coral Laboratories Limited Announces Change in Registered Office Address	Nov. 24	CI
Coral Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Coral Laboratories Limited Approves the Shifting of Registered Office	23-08-12	CI
Coral Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-12	CI
Coral Laboratories Limited Approves Alteration of Memorandum of Association	23-08-11	CI
Coral Laboratories Limited Proposes Alteration of Memorandum of Association of the Company	23-07-11	CI
Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-23	CI
Coral Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Coral Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-11	CI
Coral Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-27	CI
Coral Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-27	CI
Coral Laboratories Limited Receives Resignation of Sanket Mehta as Independent Director	22-02-24	CI
Coral Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-11	CI
Coral Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12	CI
Coral Laboratories Limited Announces the Resignation of Purvi Doshi as Non -Executive Director of the Company	21-09-17	CI
Coral Laboratories Limited Appoints Rajendrasinh Rana as an Additional Director	21-09-03	CI
Coral Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-13	CI
Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-28	CI
Coral Laboratories Limited Appoints Malay Doshi as an Additional (Independent) Director	21-05-27	CI

Chart Coral Laboratories Limited

Duration

Period

More charts

Company Profile

Coral Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical formulations. The Company is engaged in the manufacturing of generic - branded, nutraceuticals, over the counter (OTC) and herbal medicines. It offers dosage forms, which include tablets, capsules, liquid orals, injections (liquids and powder), ointment and creams, gels and lotions, and suppositories. Its product categories include nutraceutical, OTC, sterile and non-sterile. Its nutraceutical products include DAX 200, DAX 400 Drops, Zest drops and Super Zestcal Tablets. Its OTC products include herbal range, skin care, medical devices and effervescent range. Its sterile products include small volume liquid - injectables, lyophilized range - injectables, eye drops and ear drops. Its non-sterile antibiotics/antibacterials, antifungals, gastro-intestinal drugs, anti-emetics and muscle relaxants. The Company also exports its products to various countries.

Sector

Pharmaceuticals

Calendar

2024-05-21 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CORAL LABORATORIES LIMITED	-12.94%	16.04M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.60%	364B
MERCK & CO., INC.	+20.83%	326B
ABBVIE INC.	+5.69%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.77%	167B
PFIZER, INC.	+0.10%	161B

Other Pharmaceuticals